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The nature of renal cell injury. The main functional change in patients
with acute renal failure (ARF) is a decrease in glomerular filtration rate
(GFR). The virtual complete recovery of renal function in those patients
who survive ARF, as well as the minimal renal histological abnormalities
during ARF when the GFR is less than 10 mI/mm, suggest that a major
component of the renal tubular cell injury is sublethal or reversible.
Experimental models of acute tubular necrosis frequently have placed the
emphasis on irreversible proximal tubular cell death. The nature of the
renal tubular cell injury in ischemic acute renal failure, however, includes
not only cell death (necrosis or apoptosis) but also sublethal injury causing
cell dysfunction. The role of intracellular calcium, the calcium-dependent
enzymes calpain, phospholipase A2 and nitric oxide synthase (NOS), in
the pathophophysiology of this renal tubular cell injury during hypoxia!
ischemia is described. The effects of calpain and nitric oxide (NO) on the
cytoskeleton and cell adhesion are discussed. Potential mechanisms
whereby tubular injury leads to a profound fall in GFR, including
increased tubuloglomerular feedback and increased distal tubular obstruc-
tion, in ischemic acute renal failure are proposed.
Acute renal failure (ARF) is a very common renal disease
affecting about 5% of all hospitalized patients [1]. ARF still
carries a very high mortality of more than 50% and there has been
no significant change in mortality over the last four decades [1].
The course of the illness is highly variable, ranging from a
transient disease lasting less than one week and associated with
full recovery of renal function, to a disease persisting for longer
than one month and requiring dialysis and intensive care manage-
ment. There is no clear relationship between the severity of the
initial ischemic insult and the course of the illness. However, there
is a correlation between the duration of the kidney dysfunction
and mortality from ARF. Thus, a better understanding of the
pathogenesis of ARF is needed to allow interventions that would
prevent the need for hemodialysis, shorten the course of ARF and
improve survival.
The main functional change in patients with acute renal failure
is a decrease in glomerular filtration rate (GFR) and its conse-
quent effects on uremic toxin accumulation, fluid, electrolyte and
acid-base balance. Patients with renal, as opposed to prerenal,
causes of ARF have a urinary sodium concentration that exceeds
40 mmol per liter and a fractional excretion of sodium of greater
than 1% [2]. This type of renal injury is called "acute tubular
necrosis" (ATN). However, in most cases of human acute tubular
injury, in contrast to experimental models of hypoxia and ischemia
of proximal tubules, there is insufficient tubular cell death to
account for the pathophysiology of ATN [3]. The morphologic
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nature of human renal tubular cell injury is more frequently
sublethal and includes swelling and vacuolization of cells, surface
changes (loss of brush border, apical blebbing, loss of basolateral
infoldings) and cell loss [4]. However, experimental models of
tubular cell death continue to be studied and have yielded
substantial important information on the pathophysiology of renal
injury [51. Hence, the nature of the renal tubular cell injury in
ischemic acute renal failure includes both cell death (necrosis or
apoptosis) and sublethal injury causing cell dysfunction (Fig. 1).
This paper reviews the pathophysiology of renal tubular and
vascular injury with respect to understanding the nature of the
injury in patients with ARF.
Calcium
Numerous studies over the last 10 years in our laboratory have
demonstrated the central role of Ca24 in the pathophysiology of
hypoxia-induced renal injury [6—13]. None of these studies, how-
ever, conclusively demonstrated that hypoxia is associated with a
rise in free cytosolic calcium ([Ca2]1) in the proximal tubule
which precedes any evidence of membrane damage. To investi-
gate this important question, a video imaging technique was
developed in which [Ca2]1 could be measured simultaneously
with propidium iodide (P1) staining of nuclei as an index of
hypoxia-induced membrane damage [14]. PT enters the cell
through the damaged plasma membrane and stains the cell
nucleus. Hypoxia in rat proximal tubules is associated with a
significant rise in [Ca2]1 that antecedes evidence of membrane
damage as assessed by P1 staining [15]. [Ca2I1 increased from 170
to 390 nM during five minutes of hypoxia. The increase in [Ca2I1
preceded P1 detectable cell injury (Fig. 2). The increase in [Ca2]
that preceded the hypoxic membrane damage was promptly
reversible with re-oxygenation after eight minutes of hypoxia. This
is important because if [Ca2] is increased only after lethal cell
membrane damage, re-oxygenation should not have normalized
[Ca2]1. The 10 minute [Ca2]1 rise correlated significantly with
subsequent cell damage observed at 20 minutes. The pivotal role
of the rise in [Ca2] during hypoxia was further demonstrated by
using the intracellular Ca2 chelator 1,22-Bis(2-aminophenoxy)
ethane-N,N,N',N'-tetraacetic acid (BAPTA) to prevent the rise in
[Ca2]1; this approach resulted in marked cytoprotection against
hypoxic tubular injury. This study provided an important basis for
the investigation of the role of Ca2-dependent enzymes in the
pathophysiology of ARF. Two potential enzymes are (1) calpain,
a cytosolic Ca2-dependent cysteine protease, and (2) nitric oxide
synthase (NOS), which has Ca2tdependent or constitutive iso-
forms, namely neuronal NOS (nNOS) and endothelial NOS
(eNOS), and a Ca2-independent inducible form (iNOS).
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Calpain is known to be a mediator of hypoxic/ischemic injury to
brain, liver and heart [16—20]. It has recently been demonstrated
that calpain is a mediator of hypoxic injury in renal proximal
tubules [21]. In this study, the increase in calpain activity preceded
cell membrane damage and increased further during hypoxia.
Inhibition of hypoxic- and ionomyciri-induced increases in calpain
activity with the chemically-dissimilar cysteine protease inhibitors,
(2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl
ester (E-64-d) and N-benzyloxycarbonyl-Val-Phe-Methyl ester
(Cbz-Val-PheH), elicited cytoprotection against accompanying
proximal tubule cell membrane damage [211.
The development of cell permeable cysteine protease inhibitors
has facilitated the study of the role of calpain in cell injury 1221.
However, commonly used calpain inhibitors bind to the active
cysteine site on cysteine proteases and therefore inhibit other
cysteine proteases such as the cathepsins B, H, L and S in addition
to ealpain. However, a newly developed inhibitor, PD150606
[(2)-3-(4-iodophenyl)-2-mercapto-2-propenoic acid], binds to the
calcium binding site of calpain and has been recently proposed to
be a specific inhibitor of calpain and not cathepsins [23]. We have
studied the effect of this new inhibitor, PD150606, on calpain and
cathepsin activity and cell membrane damage in renal PT [24].
The selective effect of PD 150606 was demonstrated on calpain but
not cathepsins B and L in the proximal tubule. Moreover,
PD150606 elicited cytoprotection against both hypoxic- and iono-
mycin-induced cell membrane damage confirming the role of
calpain as a mediator of hypoxic injury in rat PT [24]. PD150606
thus represents a novel way to study the role of calpain in
physiological and pathological processes in the proximal tubule.
To identii' the isoform of calpain activated in rat proximal
tubules, normoxic, hypoxic and ionomycin treated tubules were
fractionated by MONO-Q anion exchange chromatography and
the fractions were assayed for calpain activity. A single peak of
calpain activity characteristic of the low calcium sensitive p-cal-
pain was found. The calcium dependency of the calpain activity
was in the nanomolar range, further confirming that the activity
was due to the low Ca24-sensitive, jx-calpain [24].
Other studies of cysteine proteases and proximal renal tubular
damage have been confined to cyclosporine [25] and HgCl2
toxicity [26]. In cultured tubules exposed acutely to cyclosporine,
calpain activity increased, but cathepsin activity was not increased
and lysosomes remained intact; these results suggested that
calpain but not cathepsins are involved in acute cyclosporine-
induced renal tubular injury [25]. In proximal tubule epithelial
cells, HgC12 toxicity correlated with increased ionized Ca2 and
the toxicity was diminished by calpain inhibitors [26].
Nitric oxide
Nitric oxide (NO) has been implicated in the pathophysiology
of ischemia. In mutant mice deficient in neuronal NOS activity,
cerebral infarct volumes decreased significantly 24 and 72 hours
after middle cerebral artery occlusion, and the neurological
deficits were less than those in normal mice [27].
NOS activity is increased during hypoxia in freshly isolated rat
proximal tubules. In this study, membrane damage, as assessed by
LDH release into the medium, was prevented by both a NOS
inhibitor, N-nitro-L-arginine methyl ester (L-NAME) and a NO
scavenger (hemoglobin) [28]. Additionally, a further increase in
hypoxic injury was observed when the NOS substrate, L-arginine,
was added to the hypoxic tubule suspension [28].
We have also directly measured NO with an amperometric NO
probe in suspensions of proximal tubules [29]. Hypoxia stimulated
NO release preceded cell membrane damage as assessed by LDH
release, while the NO concentration remained unmeasurable in
normoxic controls. The NOS inhibitor L-NAME prevented the
hypoxia-induced increase in NO in a dose-dependent manner in
parallel with incremental cytoprotection. The hypoxia-induced
elevation in NO and the associated cell membrane injury were
prevented by extracellular acidosis (pH 6.95). However, a well
known cytoproteetive agent, glycine, had no effect on NO produc-
tion during hypoxia. This study provided further evidence for a
pathogenetic role of NO in hypoxic proximal tubular injury.
The isoform of NOS involved in hypoxic/ischemic injury is being
investigated. In freshly isolated rat proximal tubules, we have
found immunohistochemical evidence, mRNA and protein for
both nNOS and eNOS as well as the protein for iNOS (unpub-
lished data). In primary cultures of human proximal tubules it has
been found that NOS mRNA, using a eDNA probe to the
constitutive form of the enzyme, was increased during hypoxia
[30]. In cultured bovine aortic endothelial cells exposed to hyp-
oxia, both the levels of mRNA and protein for eNOS were
increased [31]. A recent study has demonstrated that in vivo
targeting of iNOS with oligodeoxynucleotides protects the rat

































0 10 20 30
Time, minutes
Fig. 2. Free cytosolic calcium [Ca2 7 increases significantly in rat proximal
tubules during 10 minutes of hypoxia. Symbols are: (0) estimated [Ca2J;(•) PT stained nuclei. The increase in [Ca2I precedes evidence of
membrane damage as assessed by propidium iodide (P1) staining. *sig
nificant vs. time 0. (Reproduced from Kribben et al [15] with permission.)




for the cytotoxic effects of NO produced via iNOS in the course of
ischemic acute renal failure. The nonselective NOS inhibitor
L-NAME resulted in a deterioration of renal function reinforcing
the recent findings of endothelial NOS (eNOS) stimulation early
in the course of ARF and profound vasoconstriction accompany-
ing L-NAME infusion [33]. In another study, it was found that
non-selective inhibition of endothelial NOS (eNOS) with L-
NAME exacerbated acute cerebral ischemic injury [27]. These
findings reinforce the importance and possible therapeutic appli-
cations of selective NOS inhibition.
Phospholipase A2
PLA2 has been shown to be the dominant enzyme responsible
for release of free fatty acids and accumulation of lysophospho-
lipids in most tissues [34]. Most isoforms of PLA, have been
shown to be Ca2-dependent; however Ca2-independent forms
have also been described [35].
We have examined changes in PLA2 activity following exposure
of the tubules to hypoxia [36]. In this study, PLA2 enzymatic
activity was measured in cell-free extracts prepared from rat renal
proximal tubules. Both soluble and membrane-associated PLA2
activity were detected. All PLA2 activity detected during normoxia
was Ca2-dependent. Fractionation of cytosolic extracts by gel
filtration revealed three peaks of PLA2 activity. Exposure of
tubules to hypoxia resulted in stable activation of soluble PLA2
activity, which correlated with disappearance of the highest
molecular weight form (> 100 kDa) and appearance of a low
molecular weight form (—15 kDa) of PLA2. Pretreatment of
tubules with glycine prior to hypoxia blocked the release of PLA2
into the extracellular media, but not activation of soluble PLA2
activity. These studies provide direct evidence for PLA2 activation
during hypoxia, and suggest that multiple mechanisms regulate
free fatty acid release and lysophospholipid accumulation associ-
ated with hypoxic injury [36].
The mechanism of PLA2-induced cell membrane damage is
controversial. Membrane phospholipid breakdown has been ob-
served to occur in a number of tissues during ischemia [371. In
proximal tubules hypoxia has been shown to cause an increase in
free fatty acids, which was initially believed to contribute to cell
injury [38]. However, a recent study from our laboratory has
shown that unsaturated free fatty acids protect against hypoxic
injury in proximal tubules and that this protection may be
Fig. 3. The normal distribution of Na,K-A TPase
in the proximal tubule. Sodium from the tubular
fluid enters the tubular cell across the apical
membrane through apical channels and
cotransporters. It travels down its electrochemical
gradient and provides the driving force for
hydrogen ion secretion and glucose, amino acid
and phosphate reabsorption. Sodium is then
actively transported across the basolateral
membrane by Na,K-ATPase.
mediated by negative feedback inhibition of PLA2 activity [39].
This protective effect of unsaturated free fatty acids has been
confirmed by Zager et al [40]. The injurious effect of PLA2 could
be related to a direct disruption of cell membrane integrity by
attacking the phospholipid component of cell membranes or
through accumulation of lysophospholipids, which have been
shown to disrupt cell membranes and cause cytotoxicity [41].
Altered renal tubular cell polarity during injury
The structural polarity of the proximal tubule cell is essential
for its primary function of selective reabsorption of molecules
from the tubular fluid. The surface membrane is organized into
distinct apical and basolateral domains [42—44]. Actin is distrib-
uted along the basolateral membrane as part of the cortical web
[42]. This actin is linked by the actin-associated proteins, ankyrin
and spectrin, to basolateral cell surface proteins such as Na,K-
ATPase. The normal localization of Na,K-ATPase to the basolat-
eral membrane is regulated by direct interactions with the actin-
associated cytoskeletal proteins ankyrin and spectrin [45, 461.
The apical surface of the proximal tubule consists of the brush
border, which is the specialized area for reabsorption and contains
microvilli. The backbone of the microvillus consists of actin
microfilaments that are cross linked by the actin associated
proteins, namely ezrin, villin, myosin I and fimbrin [71 It has
been demonstrated that cytoskeletal dissociation of ezrin occurs
during anoxia in rabbit proximal tubules [48] and that this ezrin
dissociation may initiate microvillar breakdown during anoxia.
Alterations in proximal tubule cell polarity occur during renal
ischemia. Antimycin A-induced ATP depletion causes a conver-
sion of monomeric (G) actin to polymeric (F) actin in cell culture
[49]. Dissociation of the cortical cytoskeleton accompanies this
disruption of the actin microfilament network. In vivo, Na,K-
ATPase and spectrin become Triton X-100 soluble (cytoskeletal
dissociated) with the Na,K-ATPase being free of actin and
spectrin during ATP depletion [50, 51].
The basolateral location of Na,K-ATPase generates an electro-
chemical gradient across the tubule cell that is responsible for the
vectorial sodium transport from the tubule lumen to the peritu-
bular circulation (Fig. 3). This redistribution of Na,K-ATPase
from its basolateral location in the tubular cell has been suggested
as an explanation for the high fractional excretion of sodium that
is characteristic of the urine of patients with postischemic acute
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renal failure. A study by Alejandro et a! has shown that redistri-
bution of cytoskeletal proteins from the basolateral surface of the
proximal tubule is associated with delayed renal allograft function
[521. Renal tissue was sampled intraoperatively from transplanted
kidneys. Recipients, from whom tissue was sampled, were divided
into two groups: those with immediate function of the trans-
planted kidney and those with delayed graft function (decreased
GFR and impaired reabsorption of sodium). This tissue was
stained with specific antibodies against Na,K-ATPase, spectrin
and ankyrin. The distribution of cytoskeletal proteins was ana-
lyzed by laser confocal microscopy. A significant redistribution of
Na,K-ATPase, spectrin and ankyrin from the basolateral mem-
brane to the cytoplasm was confined to the group with delayed
graft function. These authors postulate that the decreased proxi-
mal tubule reabsorption of sodium leads to increased distal
sodium delivery to the macula densa, increased tubuloglomerular
feedback, and finally a decreased GFR in the kidneys with delayed
graft function. The physiological signal that triggers internaliza-
tion of plasma membrane Na,K-ATPase and dissociation of
spectrin and ankyrin following post ischemic damage is unknown.
Calpain and loss of tubule cell polarity
Cytoskeletal and cell-membrane organizational proteins that
anchor cytoskeletal elements to the plasma membrane are excel-
lent substrates for calpain [531. For example, calpain cleaves
actin-binding proteins such as spectrin, talin, filamin, alpha-
actinin and ankyrin [54]. Calpain mediated irreversible modifica-
tion of spectrin, a major lining anchor protein beneath the plasma
membrane in the brain, contributes to ischemic neuronal mem-
brane damage [17, 18]. Specifically, ischemia of hippocampal
neurons triggers proteolysis of cytoskeletal spectrin, and inhibi-
tion of this calpain-mediated proteolysis protects hippocampal
neurons from ischemia [17, 181.
The interaction between Na,K-ATPase and cytoskeletal actin-
associated proteins is important in the localization of Na,K-
ATPase to the basolateral membrane [551. The internalization of
Na,K-ATPase from the membrane could be a consequence of
calpain-mediated disruption of its interaction with the actin-
associated proteins ankyrin and spectrin. The potential effect of
calpain on cytoskeletal proteins is shown in Figure 4. In this
regard, it has been demonstrated that the early hypoxia-induced
loss of Na,K-ATPase polarity in proximal tubules is associated
with specific calpain regulated spectrin processing [56]. Cytoskel-
eta! dissociation of actin and the proteolysis of spectrin during
hypoxia in freshly isolated rat proximal tubules is mediated by
calpain [57]. In vivo, the significance of this calpain mediated loss
of polarity would be to decrease proximal tubule reabsorption of
sodium, increased distal sodium delivery to the macula densa,
increased tubuloglomerular feedback, and finally, a decreased
glomerular filtration rate (GFR).
Recently, several groups have developed antibodies that recog-
nize the specific calpain cleavage products of spectrin but not
native uncleaved spectrin [58—60]. This is a major advance that
allows for immunohistochemical detection of evidence for calpain
activation as well as study of the specific effects of calpain on
spectrin in the intact cell. Indeed, immunohistochemical evidence
of calpain mediated proteolysis of spectrin has now been shown
during brain ischemia [60].
Normally, the nature of calpain-catalyzed proteolysis is thought
to be regulatory rather than digestive, proceeding in a limited
manner and resulting in alteration rather than destruction of
substrate proteins. However, limited proteolysis by calpain may
proteolyze the actin associated proteins like spectrin, ankyrin or
Na,K-ATPase itself or cause destabilization of the structural
rigidity of proteins, making them more sensitive to attack by other
cellular enzymes, such as attack by NO, and thereby facilitating
further degradation of the substrate protein [54]. Thus, calpain
may function in hypoxia primarily as a facilitator of tubular
dysfunction rather than being the ultimate destroyer of cells.
Nitric oxide and the cytoskeleton
There is now evidence that NO can disrupt the actin cytoskel-
eton. In endothelial cells the redistribution of F-actin induced by
phorbol myristate acetate (PMA) was arginine dependent [61]. In
the gut, a high concentration of NO disrupts the actin cytoskele-
ton, inhibits ATP formation, dilates cellular tight junctions and
produces a hyperpermeable state [62]. The mechanism of these
NO-induced actin changes is potentially interesting. A decrease in
ATP is known to promote polymerization of actin in cultured
proximal tubules [43, 44, 50, 51, 63]. NO directly damages DNA
[64—66] and this activates poly (ADP-ribose)synthetase (PARS)
[67]. PARS activation severely depletes cellular NAD and ATP
levels [68, 69]. Similar results have been observed in islet cells [70,
71], where it was shown that NO-mediated PARS activation and
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Fig. 4. Potential cytoskeletal targets of calpain
during hypoxia/ischemia in proximal tubules.
Abbreviations are: ANK, ankyrin; CAM, cell
adhesion molecule; 4.1, protein 4.1.
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associated NAD depletion and toxicity were prevented by PARS
inhibition. Enhanced activation of PARS also promotes ribosyla-
tion of proteins utilizing NAD as substrate. In human neutrophils,
actin is a substrate for NO-dependent ADP ribosylation and this
modification is associated with the inhibition of actin polymeriza-
tion [72, 731 Moreover, benzamide, a PARS inhibitor, induces
changes in the actin cytoskeleton [74]. It is possible that microvil-
lar F-actin in proximal tubules is a target for NO-induced PARS
activity. Thus, NO has the potential to disrupt the actin cytoskel-
eton via inhibition of ATP formation and ADP ribosylation, both
of which can inhibit actin polymerization [61, 62, 67, 72—74].
These changes in actin could lead to proximal tubule microvillar
sloughing. This tubular debris no doubt provides substrate for
tubular obstruction, which would also contribute to the decrease
in GFR in ARF.
Nitric oxide, calpain and cell adhesion
NO is a powerful oxidant that can affect adhesion of epithelial
cells to their matrices [75]. The stress-related loss of the polarized
distribution of integrins has been shown in proximal tubules [76].
Components of integrin receptors are known substrates for cal-
pain and NO [77, 78]. In fact, both calpain and NOS inhibition
prevent cell detachment from the extracellular matrix in cultured
renal epithelial cells [79]. The potential role of calpain and NO in
proximal tubule cell detachment during hypoxic or ischemic injury
is intriguing but remains to be elucidated. Changes in actin may
also affect binding of integrins to their ligands. For example,
stress-induced depolymerization of F-actin may represent an
important mechanism for rapid changes in the binding of integrins
to their ligands in the extracellular matrix [43, 80, 81]. On this
background, it could be hypothesized that either NO, calpain or
both cause decreased cell adhesion that results in proximal tubule
detachment from the extracellular matrix. The role of these
detached but viable tubular cells in causing tubular obstruction is
potentially interesting.
Tubular obstruction in renal cell injury
Tubular obstruction is an important pathophysiological event in
the oliguria of acute renal failure [82—85]. Early studies showed
that one hour of ischemia causes a dramatic increase in proximal
tubular pressure [83]. The potential mechanism of tubular ob-
struction and increased proximal tubular pressure in ARF has
been investigated. It was originally thought that necrotic tubular
cells were the major components of casts obstructing the tubular
lumen. However, recent studies have found the presence of viable
tubular cells in the urine of patients with ARF [4, 86]. This raises
the alternative possibility that exfoliation of viable tubular cells is
the cause of tubular obstruction. It has been demonstrated in
tubular cells exposed to oxidative stress that detachment of viable
tubular cells is caused by reorientation of integrins from a
predominantly basolateral location to the apical membrane where
they can mediate cell-cell adhesion via an arginine-glycine-aspar-
tic acid (RGD) inhibitable mechanism [76]. The RGD sequence is
the most common domain contained in a variety of matrix
proteins and serves as the recognition site for various integrin
receptors [87—89]. A subsequent in vivo study demonstrated that
infusions of a synthetic RGD peptide into the renal artery during
the reperfusion period abolished the characteristic elevation of
proximal tubular pressure that served as an index of tubular
obstruction [90]. The most recent study demonstrated that sys-
temic administration of two highly potent cyclic RGD peptides
infused after the release of renal artery clamp ameliorated
ischemic acute renal failure in rats [91]. This study also suggested
that cyclic RGD peptides inhibited tubular obstruction by pre-
dominantly preventing cell to cell adhesion, rather than cell to
matrix adhesion. Another potential mechanism of tubular ob-
struction is the binding of tubular cells to Tamm Horsfall protein
(THP) or uromodulin. THP is the most abundant protein in the
urine [92] and is made exclusively in the epithelial cells of the
thick ascending limb of the loop of Henle and the early part of
the distal convoluted tubule [931. THP binds to cellular debris in
the urine from the proximal tubule, forms a cast in the tubule
lumen and obstructs further flow of urine [92]. Whether tubular
cells seen in THP casts are merely physically trapped or whether
there are specific receptor-ligand interactions between THP and
exfoliated tubular cells is not known. THP released in the tubule
tends to gel, potentially aided by a rise in concentration of sodium
and other ions in the tubular fluid. Thus, increased distal delivery
of sodium in the nephron in acute renal failure would also
promote THP to a gel form. The protein sequence of THP is
known and there is an RGD sequence at position 143-145 [94].
The functional significance of the RGD peptide on THP was
suggested by a study that found that neutrophil adhesion to THP
was inhibited by synthetic RGD peptides [95]. It is possible that
the detached tubular cells adhere to THP in the distal tubule via
the RGD sequence. This adhesion of viable tubular cells to the
large THP may promote tubule cast formation, distal tubular
obstruction and decreased GFR. This is supported by the dem-
onstration that some larger proteins, such as osteopontin, have an
RGD sequence that interacts with integrins to promote an
opposite effect to that of small synthetic RGD peptides, namely
cell adhesion [96].
The proposed mechanism of calpain and NO induced decrease
in glomerular filtration rate is shown in an abbreviated manner in
Figure 5.
Infiltrating activated leukocytes
In ischemic tissue, extravasated neutrophils adhere to the
vascular endothelium. After adherence and chemotaxis, the neu-
trophils release reactive oxygen species and enzymes that damage
the tissue [971. Infiltrating leukocytes play a pathogenetic role in
mildly ischemic kidneys [98]. It has also been shown that while
infusion of normal neutrophils accentuate severe ischemia/reper-
fusion injury, oxygen metabolite deficient neutrophils from
chronic granulomatous disease patients do not. Intracellular
adhesion molecule I (ICAM-1) on endothelial cells promotes the
adhesion of neutrophils to these cells [99, 100]. The administra-
tion of a monoclonal antibody against ICAM-1 protects against
ischemic ARF and mice with a deficiency of ICAM-1 are also
protected against ARF [101, 102]
Nitric oxide/superoxide balance
The pathway generally invoked for ultimate hydroxyl radical
formation involves the presence of superoxide (O2), hydrogen
peroxide and additionally either iron or copper ions. However,
given the rate constant for the reaction of NO with 02 compared
to its dismutation [103], it is possible that O2 may act to
counteract the effect of excess NO production during hypoxia by









Fig. 5. Proposed mechanism of calpain and
nitric oxide (NO)-induced decrease in glomerular
filtration rate (GFR) during ischemia. THP is
Tamm Horsfall protein.
inactivating it. In this regard, Hobbs, Fukuto and Ignarro [104]
have clearly shown that the addition of the 02 generating
system, xanthine/xanthine oxidase (X/XO), to NO in solution
results in a prompt drop in the detected level of NO. In other
studies, the importance of the balance of NO and 02 was
similarly shown. In these studies, cytotoxicity resulting from
hypoxanthine/XO exposure in Chinese hamster lung fibroblasts
was markedly abrogated by NO [105]. In freshly isolated rat
proximal tubules, we have shown that O2 generation by X/XO
reduces the NO level and has a protective effect on hypoxic
damage [106]. These results suggest that under physiological
conditions, NO and O2 are in balance and neither is toxic; during
hypoxia, however, NO is in excess and becomes toxic. It has also
been shown that superfusiori of the mesenteric microcirculation
with NO donors significantly reduced the ischemia/reperfusion-
induced leukocyte adherence/emigration and albumin leakage in
post-capillary venules [107]. Thus, it would be expected that NO
would be protective against reperfusion injury by reducing leuko-
cyte adherence/emigration and subsequent release of damaging
reactive oxygen species. Indeed, Linas, Whittenburg and Repine
have shown that, while NO worsens ischemic injury in the absence
of leukocytes, it prevents the leukocyte component of ischemic
renal injury by blocking the injurious effect of activated leukocytes
on glomerular and tubular function [108]. During reoxygenation,
a toxic level of O2 may therefore be generated [106].
Vascular factors and renal injury
The duration of ARF is highly variable and there is no clear
relationship between the duration of the illness and the severity of
the initial insult [109, 110]. An important finding regarding the
variable duration and prolonged course of ARF was the presence
of fresh renal ischemic lesions in biopsy or autopsy specimens of
patients with ARF as late as three weeks after the initial ischemic
event and unrelated to the initial ischemic insult [111]. A possible
predisposing factor to recurrent ischemic injury and prolongation
of ARF is aberrant renovascular reactivity, a consequence of the
ischemic process that initiated the ARF. Indeed, loss of renal
blood flow autoregulation has been found in experimental models
of ARF at 48 hours after the ischemic insult [112—115]. In the
norepinephrine ARF model in rats there was paradoxical vaso-
constriction with renal perfusion pressure reduction in the auto-
regulatory range [113, 116]. Other abnormalities of the renal
vasculature have been found in experimental models of ARF.
There is injury to the endothelial lining of renal blood vessels,
which may be related to calcium overload in vascular and/or
endothelial cells, since verapamil and diltiazem partially obviate
the loss of autoregulatosy ability and hypersensitivity to renal
nerve stimulation [117]. The mechanism of the post-ischemic
renovascular hypersensitivity has been studied. There is an atten-
uated vasodilator response to acetylcholine directly after ischemia
when renal blood flow is 50% of normal [118], despite marked
constrictor responses to NOS inhibitors [119]. This can be ex-
plained by maximal or near maximal NOS/NO stimulation in the
basal state of ischemic vascular injury that cannot be stimulated
further by endothelium-dependent vasodilators. This possibility
has been supported by the demonstration that vasodilation to the
NO donor, sodium nitroprusside, is blunted because NO stimu-
lation of cGMP in smooth muscle cells is already maximal while
vasodilation to cAMP-dependent prostacyclin is preserved [33].
This finding of intact endothelial NOS/NO function at the peak of
renovascular hypersensitivity post-ischemia points to an intrinsic
defect in the smooth muscle cell of the vessel wall or perhaps an
increased endogenous paracrine constrictor agonist activity. In
examining the mechanism for this defect, measurements of
smooth muscle cell calcium have been made in isolated arterioles
[120]. Compared to similar vessels from sham-ARF kidneys, there
is a significantly higher baseline and earlier and greater increase in









Edelstein et a!: Nature of renal cell injuly 1347
correlates with the initially lower and more intense reduction in
lumen diameter in the post-ischemic ARF vessels. The mecha-
nism of the basal increase in smooth muscle cell calcium and the
exaggerated increase in response to a constrictor agonist remain
to be determined.
Cyclosporine is the most widely used immunosuppressive drug
in renal transplantation. It can cause acute or chronic renal
dysfunction [121]. Acute cyclosporine nephrotoxicity is a revers-
ible model of vascular injury. It is characterized by decreased
glomerular filtration rate and a reduction of renal blood flow
without permanent morphological changes. There is vasoconstric-
tion of the afferent arteriole [122]. In rats given cyclosporine for
one to two weeks, there was decreased renal vasodilation to
acetylcholine [123, 124] and vasoconstriction to NOS inhibition
[124], but a normal response to sodium nitroprusside [125]. These
studies suggest a decrease in endothelial NOS production in acute
cyclosporine toxicity. Similarly, low dose cyclosporine exposure
for two weeks significantly attenuated the vasodilator effects of
acetyicholine and the vasoconstrictor effect of L-NAME [33].
L-arginine loading in rats exposed to cyclosporine also improves
renal hemodynamics [124]. Thus, in summary, intact endothelial
NOS production plays a role in the protection against cyclospor-
inc toxicity.
Calcium channel blockers, which are known to dilate the
afferent arteriole, also reduce the incidence of post-transplant
acute tubular necrosis and renal dysfunction [126, 127].
Atrial natriuretic peptide (ANP) in an extract of mammalian
atrial myocytes was first described by de Bold et a! in 1981 [128].
ANP is an ideal substance to counteract the two proposed
pathophysiological mechanisms of decreased GFR in ARF,
namely reduced glomerular perfusion and tubular obstruction.
Infusion of ANP markedly increases GFR with a lesser increase in
renal blood flow [129]. There is, however, also a dose dependent
decrease in systemic arterial blood pressure. ANP protects against
ischemic acute renal failure in rats even when administered after
the ischemic insult [130]. In a prospective study of human acute
renal failure, renal function improved up to 24 hours after
termination of the infusion of ANP and the treated group had a
reduced requirement for dialysis as compared with the non-
treated group [131]. Preliminary results from a large multicenter
study of ANP in human ARF suggest that these agents may be
useful in patients with oliguric ARF [132].
Therapeutic role of growth factors
The growth factors, insulin-like growth factor I (IGF-I), epider-
mal growth factor (EGF) and hepatocyte growth factor (HGF),
are known to bind specific receptors in the proximal tubule and
regulate metabolic, transport and proliferative responses in these
cells [J33]. Expression of HGF and its receptor is increased after
unilateral nephrectomy and renal injury in rats [134]. EGF
enhances renal tubule cell regeneration and repair and acceler-
ates the recovery of ischemic acute renal failure [1351. Both HGF
and IGF-1 accelerate the recovery of normal renal function and
regeneration of damaged proximal tubular epithelium and im-
prove the mortality in postischemic rat tubular injury [136, 1371.
Clinical studies of IGF-1 in ARE are under way [138].
Apoptosis
Apoptosis is the name given to a process of physiologic or
programmed cell death. Apoptotic cells undergo a series of
morphologically identifiable changes in their pathway to cell death
[139]. Several genes are now known to direct and execute cell
death due to apoptosis, and the gene for the enzyme known as
interleukin-1-beta-converting enzyme (ICE) has recently been
shown to promote programmed cell death [140]. Thus, in addition
to necrosis, cell death in proximal tubules can potentially also be
mediated by apoptosis. Pathological evidence of apoptosis has
been found in postischemic kidneys in animals [141, 1421, clinical
acute renal failure in humans [143] and in post-transplantation
ARF where it coexists with necrosis [144]. Endogenous endonu-
clease activation, resulting in DNA fragmentation, is considered a
characteristic biochemical marker for apoptosis [145]. However,
DNA fragmentation also occurs in cellular necrosis. In this regard,
endonuclease activation and DNA fragmentation has been found
in hypoxia/reoxygenation necrotic injury in proximal tubules with
no morphological evidence of apoptosis by light or electron
microscopy [1451. Also, in both postischemic rat kidneys and
posthypoxic rat proximal tubules in suspension, minimal DNA
laddering develops and it correlates with morphologic expression
of tubular necrosis and not apoptosis [146]. The differentiation of
apoptosis from necrosis in tubular cells therefore is still difficult
[147] and requires both demonstration of DNA fragmentation,
usually using a histochemical technique based on terminal deoxy-
nucleotidyl transferase (TdT) reactivity with DNA breaks, as well
as morphological evidence of apoptosis by light and electron
microscopy. The mechanism of apoptosis in tubular cells is
unknown. Increases in intracellular calcium and calcium iono-
phores are known to stimulate apoptosis. Calcium dependent
endonucleases may be responsible for DNA fragmentation. Cal-
pain activation and cytoskeletal changes have been shown in
models of apoptosis [148]. The role of apoptosis in tubular cell
dysfunction in ARF is unknown and it has been suggested that
apoptosis in proximal tubules may play a role in the removal of
damaged cells [149J.
Conclusion
The nature of the renal injury in ischemic ARF includes tubular
cell death from either necrosis or apoptosis (irreversible) and
sublethal injury that causes reversible dysfunction. In this review
we have discussed the pathophysiology of both vascular and
tubular injury (lethal and sublethal) that occurs in hypoxia!
ischemia. A mechanism for the decreased GFR in ischemic ARF,
that encompasses increased distal tubular obstruction and tubu-
loglomerular feedback, is proposed.
Reprint requests to Robert W Schrier, C28], University of Colorado School
of Medicine, 4200 E. 9th Aye, Denver, Colorado 80262, USA.
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